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Abstract
Background: Peroxisome proliferator-activated receptor gamma (PPAR-γ) has been demonstrated to be involved
in anti-inflammatory reactions, but its role in acute-on-chronic hepatitis B liver failure (ACHBLF) is unclear. Therefore,
DNA methylation patterns and expression level of PPAR-γ gene were detected in peripheral blood mononuclear cells
(PBMCs) from 81 patients with ACHBLF, 50 patients with chronic hepatitis B (CHB), and 30 healthy controls, and the
possible role of PPAR-γ in ACHBLF was analyzed.
Results: We found that aberrant PPAR-γ promoter methylation was attenuated in ACHBLF patients compared with
CHB patients and was responsible for the elevated PPAR-γ expression level, which was negatively correlated with total
bilirubin and international normalized ratio. Plasma level of TNF-α and IL-6 in ACHBLF patients were higher than CHB
patients and healthy controls and significantly reduced in unmethylated group. ACHBLF patients with PPAR-γ promoter
methylation had poorer outcomes than those without. Correspondingly, PPAR-γ messenger RNA (mRNA) level was higher
in survivors than non-survivors and gradually increased in survivors with time, while remained low level in non-survivors.
Conclusions: Aberrant promoter methylation decline and PPAR-γ expression rebound occurred in ACHBLF compared
with CHB and could improve prognosis of ACHBLF by negatively regulating cytokines.
Keywords: DNA methylation, Acute-on-chronic hepatitis B liver failure, Peroxisome proliferator-activated receptor gamma,
Cytokines, Prognosis
Background
Hepatitis B virus (HBV) infection is one of the most serious
public health problems, affecting more than two billion
people worldwide. There are more than 350 million chronic
carriers, 75 % of whom reside in the Asia Pacific region [1].
Reactivation of HBV infection is a major cause for acute de-
terioration of liver function manifesting as jaundice and co-
agulopathy, which is a severe life-threatening condition
termed acute-on-chronic hepatitis B liver failure (ACHBLF)
[2]. It is demonstrated that pro-inflammatory and anti-
inflammatory cytokines play a crucial role in the pathogen-
esis of ACHBLF and constantly influence the disease
progression. Level of several cytokines has been found
to be elevated in patients with ACHBLF, which may be
led to endotoxemia, cytokine release by necrotic liver
cells, and/or reduced hepatic removal [2–6]. Conse-
quently, elevated cytokines aggravate liver injury by me-
diating acute systemic inflammatory response and raise
the fatality rate [6]. However, the exact mechanism of
ACHBLF is not fully delineated.
Peroxisome proliferator-activated receptor gamma
(PPAR-γ) is a member of nuclear receptor supergene
family that functions in ligand-dependent transcription
[7, 8]. The PPAR-γ is abundantly expressed in adipose
tissue, colon, spleen, and macrophages and is believed
to play a role in adipocyte differentiation, lipid metabol-
ism, and glucose homeostasis by exerting effect on gene
transcription [9–12]. Recently, accumulating evidence
has demonstrated that PPAR-γ is involved in anti-
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inflammatory reactions both in vitro and in vivo. Sev-
eral studies have investigated the effects of PPAR-γ ac-
tivation on the inflammatory responses of monocytes
and macrophages. It is shown that PPAR-γ activation
can inhibit the expression of the inducible nitric oxide
synthase (iNOS), gelatinase B, and scavenger receptor
A genes in response to PPAR-γ ligands and can also in-
hibit inflammatory gene expression in part by antagon-
izing the activities of the transcription factors AP-1,
STAT, and NF-kB in transfected cell lines [13, 14]. Add-
itionally, it is revealed that PPAR-γ functions to
dampen inflammation and injury and synthetic agonists
remarkably activate PPAR-γ and amplify the effect in
animal models of acute lung injury [15]. Similar results
are observed in colitis [16] and acute pancreatitis [17]
in vivo. All these findings suggest that PPAR-γ may
serve as an anti-inflammatory mediator and play a pro-
tective role in inflammatory diseases.
In our previous study, we found PPAR-γ was signifi-
cantly down-regulated due to promoter hypermethylation,
and its expression level was correlated with intrahepatic fi-
brosis and inflammation grade in patients with chronic
hepatitis B (CHB) [18]. ACHBLF is quite a different situ-
ation from CHB, which is basically a transition from the
chronic phase into the fulminant phase and manifests as a
process of acute decompensation of liver function. Con-
sidering the widely different mechanisms underlying the
two situations, it is still of great importance to examine
the role of PPAR-γ in ACHBLF. Therefore, it arouses our
interest to detect the change of promoter methylation
status and expression of PPAR-γ gene and its possible role
in the acute event.
Therefore, the current study aimed to determine the pro-
moter methylation patterns and expression of PPAR-γ gene
and plasma level of inflammatory cytokines in patients
with ACHBLF to explore the role of PPAR-γ in the pro-
gression and prognosis of ACHBLF and test its possibility
to be used as a biomarker for prediction and surveillance.
Results
General characteristics of subjects
The selection process for subjects enrolled is shown in
Additional file 1: Figure S1. Eventually, 81 ACHBLF pa-
tients, 50 CHB patients, and 30 healthy controls were en-
rolled in the present study. The demographic and clinical
characteristics are shown in Table 1.
Methylation frequency of PPAR-γ promoter in patients
with ACHBLF
We first detected the methylation status of two CpG
islands in PPAR-γ promoter in all enrolled subjects
(Table 2). The methylation frequency of PPAR-γ promoter
in ACHBLF patients was significantly decreased compared
with CHB patients (CpG-1, χ2 = 8.918, P = 0.003; CpG-2,
χ2 = 9.268, P = 0.002), however, was still greatly higher
than healthy controls (CpG-1, χ2 = 6.691, P = 0.009; CpG-
2, χ2 = 5.050, P = 0.025). Also, we found that methylation
frequency of both CpG islands in CHB patients was prom-
inently higher than healthy controls (CpG-1, χ2 = 21.333,
Table 1 Baseline characteristics of the subjects enrolled in the study
ACHBLF CHB HC
Cases (n) 81 50 30
Age (years) 44.25 ± 13.65 41.80 ± 14.04 41.57 ± 12.09
Gender (m/f) 57/24 35/15 21/9
HBeAg (+/-) 37/44 23/27 0/30
Log10 [HBV DNA] 5.16 ± 1.71 5.64 ± 1.64 NA
ALT (U/L) 489.45 ± 642.68*,** 362.92 ± 470.21* 27.10 ± 11.55
AST (U/L) 398.61 ± 534.34*,** 183.40 ± 202.84* 26.77 ± 7.34
TBIL (μmol/L) 296.43 ± 158.18*,** 30.19 ± 38.44* 12.48 ± 5.08
Cr (μmol/L) 73.35 ± 42.66*,** 63.34 ± 13.64* 57.33 ± 12.79
ALB (g/L) 33.48 ± 8.73*,** 40.86 ± 5.67* 47.00 ± 4.53
PTA (%) 37.84 ± 9.06*,** 91.94 ± 17.39 93.60 ± 14.17
INR 1.87 ± 0.63*,** 1.02 ± 0.14 1.01 ± 0.11
Ascites (%) 76.54*,** 24.00* 0
Encephalopathy (%) 34.57*,** 0 0
Mortality (%) 54.32*,** 0 0
Data are shown as mean ± standard deviation
ACHBLF acute-on-chronic hepatitis B liver failure, CHB chronic hepatitis B, HC healthy control, HBV Hepatitis B virus, ALT alanine aminotransferase, AST aspartate
aminotransferase, TBIL total bilirubin, Cr serum creatinine, ALB albumin, PTA prothrombin activity, INR international normalized ratio, NA not available
*Versus HC P < 0.05; **Versus CHB P < 0.05
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P < 0.001; CpG-2, χ2 = 19.448, P < 0.001) (Fig. 1a), and this
was identified with our former study.
Hypermethylation of CpG islands in PPAR-γ gene promoter
resulted in down-regulation
Due to the fact that alteration of promoter methylation sta-
tus is a usual mechanism affecting transcriptional activity,
we then measured the expression level of PPAR-γ. The
messenger RNA (mRNA) level of PPAR-γ in subjects with
or without methylation was compared. The results showed
that relative expression of PPAR-γ was significantly de-
creased with either CpG-1 (Z = −6.613, P < 0.001) or CpG-
2 (Z = −7.712, P < 0.001) island methylation (Fig. 1c, d),
and the suppression seemed to be superposable (both MU
vs. one MU, Z = −4.085, P < 0.001) (Fig. 1e). The data con-
firmed our deduction and were basically in agreement with
our previous study.
Correlation between increased PPAR-γ mRNA level and
clinical parameters in patients with ACHBLF
Moreover, we found that PPAR-γ mRNA level was signifi-
cantly elevated in ACHBLF patients compared with CHB
patients (Z = −4.003, P < 0.001) (Fig. 2a). However, PPAR-
γ mRNA level was significantly lower in ACHBLF patients
than that in healthy controls (Z = −4.632, P < 0.001).
Meanwhile, expression of PPAR-γ was significantly lower
in CHB patients than healthy controls (Z = −6.037, P <
0.001). These results were corresponding with the alter-
ation of promoter methylation status we observed and
showed above. To further study the role of PPAR-γ in
ACHBLF, we combined with clinical data that reflected
liver function of the patients. Linear correlation analysis
showed that expression of PPAR-γ was negatively cor-
related with total bilirubin (TBIL) (r = −0.280, P =
0.011, Fig. 2c) and international normalized ratio (INR)
(r = −0.230, P = 0.039, Fig. 2d). No significant correl-
ation was found between PPAR-γ mRNA level and alanine
aminotransferase (ALT), creatinine (Cr), or HBV-DNA
load in patients with ACHBLF (Fig. 2b, e, f). These data
Table 2 A cross table for methylation status of two islands in all
subjects
CpG-1 island Total CpG-2 island Total
MU U MU U
ACHBLF 35 46 81 38 43 81
CHB 35 15 50 37 13 50
HC 5 25 30 7 23 30
Total 75 86 161 82 79 161
MU for methylation and unmethylation states both presented, U for only
unmethylation status presented
Fig. 1 Methylation status of PPAR-γ promoter and comparison of PPAR-γ mRNA expression level. a The methylation frequency of PPAR-γ promoter in
acute-on-chronic hepatitis B liver failure (ACHBLF) patients was significantly decreased compared with chronic hepatitis B (CHB) patients but
was significantly higher than healthy controls (HC). b For CpG-1 island, products of methylation-specific PCR (MSP) are displayed. 218 bp M
lanes and 221 bp U lanes. M for methylation state of CpG island on PPAR-γ promoter, U for unmethylation state, N for negative control. c For
CpG-2 island, products of MSP are displayed. 138 bp M lanes and 139 U lanes. For both CpG-1 (d) and CpG-2 (e) islands, PPAR-γ mRNA expression level
was significantly lower in methylated group than that in unmethylated group. f mRNA level was decreased stepwise as methylated CpG islands added.
*P < 0.05, **P < 0.01
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suggested that PPAR-γ was closely related with the severity
of ACHBLF.
Level of cytokines and relation with PPAR-γ promoter
methylation in patients with ACHBLF
Now that PPAR-γ was shown to be involved in the dis-
ease, we tried to further study the probable mechanism.
The plasma level of TNF-α and IL-6 was assessed by
enzyme-linked immunosorbent assay (ELISA) in the
subjects. Level of both cytokines was significantly in-
creased in ACHBLF patients compared with CHB pa-
tients (TNF-α, t = 6.649, P < 0.001; IL-6, t = 6.784, P <
0.001) and healthy controls (TNF-α, t = 5.582, P < 0.001;
IL-6, t = 5.961, P < 0.001) (Fig. 3a, b). No significant
difference in level of both cytokines was found between
CHB patients and healthy controls. In patients with
ACHBLF, level of plasma cytokines in methylated group
was significantly higher than unmethylated group (TNF-α,
t = 2.312, P = 0.023; IL-6, t = 2.639, P = 0.012) (Fig. 3c).
These results implied that relative elevation of PPAR-γ ex-
pression as a result of promoter demethylation could ef-
fectively repress the pro-inflammatory cytokines.
Association between PPAR-γ promoter methylation and
prognosis of patients with ACHBLF
Considering the anti-inflammatory effect of PPAR-γ, we
speculated that PPAR-γ might alleviate the fulminant in-
flammatory injury and thus prolong the survival time of
Fig. 2 PPAR-γ mRNA level of all subjects and correlation with clinical parameters in ACHBLF patients. There was significant difference in PPAR-γ mRNA
expression level between any two of the three groups (a). PPAR-γ mRNA expression level was negatively correlated with serum total bilirubin
(TBIL) (b) and international normalized ratio (INR) (c). No significant correlations were found between PPAR-γ mRNA expression level and
alanine aminotransferase (ALT) (d), serum creatinine (Cr) (e), or hepatitis B virus (HBV)-DNA load (f). P values and r, correlation coefficient,
are shown. *P < 0.05, **P < 0.01
Fig. 3 Plasma level of cytokines in all subjects and comparison between different groups in ACHBLF patients. Level of both TNF-α (a) and IL-6 (b) was
significantly increased in ACHBLF patients than chronic hepatitis B (CHB) patients and healthy controls. c In patients with ACHBLF, level both
TNF-α and IL-6 was significantly higher in methylated group (defined as either CpG island was methylated, n = 51) than those in unmethylated
group (defined as neither CpG island was methylated, n = 30). *P < 0.05, **P < 0.01
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ACHBLF patients. So, a short-term follow-up was con-
ducted. The 3-month mortality was 54.32 % (44/81), and
the mean survival time is 53.47 (SE 4.057, 95 % CI
45.39–61.54). The PPAR-γ mRNA level of survivors was
significantly higher than non-survivor (Z = −3.489, P <
0.001, Fig. 4a). Kaplan-Meier survival curve for ACHBLF
patients with or without PPAR-γ methylation was dem-
onstrated in Fig. 4b. Prognosis of methylated group was
significantly poorer compared with unmethylated group
(χ2 = 11.140, P < 0.001). The mean survival time for meth-
ylated group and unmethylated group was 42.24 days (SE
5.113, 95 % CI 31.97–52.50) and 72.57 days (SE 5.101,
95 % CI 62.13–83.00), respectively. A continuous surveil-
lance of PPAR-γ mRNA expression level was carried out in
twenty-seven ACHBLF patients within the first 3 weeks
after admission. Data of some non-survivors were in-
complete due to the intermediate death. We noted that
PPAR-γ expression was significantly increased with time
extending in survivors (Fig. 4c), while remained low level
in non-survivors (Fig. 4d). The disparity between PPAR-γ
mRNA level of the two groups was expanded week by
week (Fig. 4e). Because of the significant relation between
PPAR-γ and prognosis of the patients, we examined its
potential use in clinical prediction. Prognostic perform-
ance was evaluated, and the receiver operating character-
istic (ROC) curve for PPAR-γ methylation, PPAR-γ
mRNA, and model for end-stage liver diseases (MELD)
score was illustrated (Fig. 4f). The areas under the ROC
curve (AUC) were 0.726 (SE 0.059, 95 % CI 0.611–0.841),
0.657 (SE 0.062, 95 % CI 0.535–0.778), and 0.725 (SE
0.056, 95 % CI 0.615–0.836), respectively.
Discussion
In this study, we firstly reported the alteration of
PPAR-γ promoter methylation status and gene expres-
sion in peripheral blood mononuclear cells (PBMCs) in
patients with ACHBLF. We found that promoter
methylation frequency was decreased and mRNA level
of PPAR-γ was elevated in ACHBLF patients when
comparing with CHB patients. Plasma level of TNF-α
and IL-6 prominently rose in patients with ACHBLF
and both cytokines level were lower in unmethylated
group than methylated group. Moreover, promoter
methylation status and mRNA level of PPAR-γ were
closely associated with prognosis of patients with
ACHBLF in the 3-month follow-up. The unmethylated
group, which also meant the group with higher PPAR-γ
expression level, showed a better outcome than the
methylated group. Dynamic observation showed that
PPAR-γ expression level was elevated in survivors while
remained low level in non-survivors.
Fig. 4 PPAR-γ mRNA level and promoter methylation predict outcomes of ACHBLF patients. a The mRNA level of PPAR-γ in survivors (n = 37) was
significantly higher than that in non-survivors (n = 44). b Kaplan-Meier graph showed that survival probability of unmethylated group (n = 30) was
higher than methylated group (n = 51) in patients with ACHBLF. Serial PPAR-γ mRNA expression level in part of survivors (n = 11) (c) and non-survivors
(n = 16) (d). e An overview of dynamic change of PPAR-γ mRNA expression level in part of survivors (n = 11) and non-survivors (n = 16). f The receiver
operating characteristic (ROC) curves of PPAR-γ expression level, PPAR-γ promoter methylation, and MELD score for predicting 3-month mortality of
patients with ACHBLF are shown (n = 81). The areas under the ROC curve (AUC) are noted. *P < 0.05, **P < 0.01
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CpG islands refer to DNA segments which are abundant
in CpG content, and CpG islands usually locate in the
promoters [19, 20]. Methylation of CpG islands in gene
promoter is an important regulating pattern of gene ex-
pression and usually results in gene silencing [21]. In our
previous study, we had already found that hypermethyla-
tion of promoter was an important mechanism in PPAR-γ
gene silencing and synchronous methylation of the two
CpG islands might exert more powerful inhibition of gene
transcription. The present data provided further confirm-
ation of the conclusion. Meanwhile, the decreased methy-
lation frequency was corresponding with the elevated
PPAR-γ expression level in ACHBLF patients.
We had known that PPAR-γ expression was significantly
down-regulated due to the hypermethylation occurred in
promoter of CHB in our former study. Compared with
CHB patients, we found that mRNA level of PPAR-γ was
elevated in ACHBLF patients. However, the rebound was
limited and failed to reach the normal level in comparison
with health controls, which meant the inhibitory effect
still existed with HBV infection. This phenomenon re-
vealed the immune system disorder in ACHBLF and could
be one of the mechanisms which contributed to the onset
and exacerbation of the disease.
Although the pathogenesis of ACHBLF still remains to
be elucidated, the important role played by cytokines has
been long focused. It is believed that imbalanced expres-
sion of pro-inflammatory and anti-inflammatory cytokines
may contribute to immunopathogenesis in ACHBLF.
Among them, TNF-α and IL-6 are two key cytokines. It
was reported that TNF-α production was increased in
acute liver failure (ALF) [22, 23]. Zou et al. found that
intrahepatic expression of TNF-α was closely correlated
with the intrahepatic CD4+ CD8+ T lymphocytes and
Kupffer cells (KCs) cellular infiltration in ACHBLF [5]. It
has also been shown that TNF-α level in ALF correlated
subsequent serious clinical complications, such as infec-
tion and encephalopathy [24–26]. Gazzard et al. reported
elevated IL-6 level with multiple organ failures and in-
creased mortality in ALF [27]. A recent study found that
IL-6 may be involved in ACHBLF by upregulating Th17
response which mediates massive tissue inflammation by
recruiting immune cells [28]. Moreover, it has been re-
ported that activation of PPAR-γ could inhibit production
of inflammatory cytokines by monocytes [14]. In agree-
ment with the above studies, we found that plasma level
of TNF-α and IL-6 in ACHBLF patients were dramatically
higher than CHB patients and healthy controls, and level
of both cytokines declined in unmethylated group com-
pared with methylated group, which meant elevation of
PPAR-γ expression level could lead to decreasing of pro-
inflammatory cytokines. Taken together, we speculated
that PPAR-γ gene expression elevation due to the attenu-
ation of promoter methylation could be a self-protective
measure under inflammatory stress by down-regulating
level of TNF-α and IL-6 which were involved in immune-
mediated liver injury in ACHBLF.
Therefore, PPAR-γ is supposed to be closely related with
prognosis of patients with ACHBLF, which was confirmed
by our 3-month follow-up. Patients without PPAR-γ
methylation had better chances to survive. PPAR-γ mRNA
level was higher and continuously elevated in survivors,
while lower and sustained at low level in non-survivors
with time extending. Thus, we evaluated the performance
of PPAR-γ to predict prognosis of patients with ACHBLF.
Although PPAR-γ methylation (AUC = 0.657) was poorer
than MELD score (AUC= 0.725), PPAR-γ expression
(AUC= 0.726) was comparable to MELD score and could
be regarded as a valuable prognostic marker. Still, more
studies focusing on the prognostic performance of PPAR-
γ are needed to verify the conclusion.
According to the Asian Pacific Association for the Study
of Liver (APASL) practice guideline, inhibition of the in-
flammatory cytokines might offer a novel approach for re-
ducing the morbidity and mortality in patients with
ACHBLF due to the fact that cytokines influence the devel-
opment and course of ACHBLF [2]. Our study suggested
that PPAR-γ might serve as a candidate treatment target
for the possibility that activation of PPAR-γ could down-
regulate pro-inflammatory cytokines and improve the
prognosis of patients with ACHBLF. Chemically synthe-
sized PPAR-γ agonists, such as thiazolidines, can selectively
activate PPAR-γ to increase the peripheral sensitivity to in-
sulin and reduce the blood glucose level and are commonly
used to treat type 2 diabetes. Recently, increasing investiga-
tions have been focused on therapeutic value of PPAR-γ
agonists in inflammatory diseases treatment. Suh et al. re-
ported that PPAR-γ ligands inhibited epithelial inflamma-
tory response in animal models of colitis, and Bordji et al.
reported the anti-inflammatory properties of PPAR-γ li-
gands in ameliorating the cytokine-induced damage to car-
tilage associated with arthritis [29, 30]. Therefore, it is
likely that PPAR-γ agonists are of therapeutic value to
some extent in ACHBLF treatment. Despite all this, more
investigations are needed to confirm the conjecture.
There are some limitations in this study. Firstly, our
sample size is relatively small, which may cause a low
Spearman’s rho value in the correlation analysis. However,
ACHBLF is a sever condition with high mortality but low
morbidity which makes it difficult to recruit a large num-
ber of patients rapidly, and the low Spearman’s rho value
is attributed to not only relative number of patients but
also other multiple factors including the basal liver func-
tion, heterogeneity of underlying diseases, and hepatic
compensative capacity, which would greatly affect the al-
teration of clinical parameters. Still, more studies with a
large scale in different cohorts are expected to validate
our results. Secondly, as discussed above, in vivo and in
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vitro experiments with PPAR-γ agonists intervention are
imperative to explore the therapeutic value of PPAR-γ ag-
onists in ACHBLF.
The interpretation is very interesting when retrospecting
the findings of our former study. PPAR-γ was believed to
be involved in hepatic stellate cells (HSCs) activation and
differentiation which was a core event in liver fibrosis and
was a pivotal gene to maintain the adipogenic phenotype
characteristics of HSCs and prevent the initiation of fibro-
sis [31]. Our former study also confirmed that silencing of
PPAR-γ due to the promoter hypermethylation contrib-
uted to the onset and progression of liver fibrosis in CHB
patients. Whereas, another important part of PPAR-γ was
demonstrated in our present study that it was actually in-
volved in anti-inflammation reactions by repressing level
of pro-inflammatory cytokines such as TNF-α and IL-6
and was a protective factor in ACHBLF. So, the predomin-
ant biological functions of PPAR-γ in different diseases
were indeed various and crucial. Furthermore, a recent
study has revealed that PPAR-γ seems to be involved in
the epigenetic regulation of miR-122 whose gene tran-
scription is enhanced as a result of increased affinity of
PPAR-γ and retinoid X receptor alpha (RXRα) complex to
the gene promoter in hepatocellular carcinoma cells [32].
In turn, PPAR-γ could also be regulated in a microRNA-
dependent way [33]. It is demonstrated that down-
regulation of miR-132 can promote the formation of an
epigenetic repressor complex inhibiting PPAR-γ expres-
sion and therefore promoting liver fibrosis in vivo [34].
These new findings suggest an exquisite role of PPAR-γ in
epigenetic regulation in the liver diseases and provide new
promising fields in which more mechanisms could be
shed light on and better efforts to improve clinical practice
might be made.
Conclusions
In conclusion, we found decreased methylation frequency
and elevated PPAR-γ expression level of PPAR-γ promoter
in ACHBLF patients compared with CHB patients. Pro-
moter methylation and expression level of PPAR-γ were
closely associated with severity and prognosis of ACHBLF.
Also, PPAR-γ may have a potential role in improving




Eighty-one patients with ACHBLF, 50 patients with CHB,
and 30 healthy controls were recruited from July 2010 to
January 2015 at Department of Hepatology, Qilu Hospital
of Shandong University. Patients with ACHBLF were de-
fined according to the consensus recommendation of the
APASL [2]. To be specific, patients with acute hepatic in-
sult manifesting as jaundice (serum bilirubin ≥5 mg/dl
[85 μmol/L]) and coagulopathy (INR ≥1.5 or prothrombin
activity <40 %), complicated within 4 weeks by ascites
and/or encephalopathy based on CHB, were considered
eligible. Patients with CHB were defined as presence of
hepatitis B s antigen (HBsAg) in serum last for more than
6 months, and there was histological evidence of chronic
hepatitis, according to the 2009 update of American Asso-
ciation for the Study of Liver Diseases (AASLD) practice
guidelines for management of chronic hepatitis B [35]. Pa-
tients were excluded if they met any of the following cri-
teria: (1) co-infected with HCV or HIV, (2) suffered from
other liver diseases such as autoimmune hepatitis and al-
coholic hepatitis, (3) receiving antioxidant agent or inter-
feron therapy, (4) pregnant, and (5) complicated with
hepatocellular carcinoma. A 3-month follow-up was con-
ducted, and the outcomes were recorded in patients with
ACHBLF. The start date was defined as the date of diag-
nosis of ACHBLF after hospital admission. There was no
ACHBLF patient received liver transplantation in the
study. Prior to sample collection, informed consent was
obtained from each participant, and the study was ap-
proved by the local Ethical Committee of Qilu Hospital of
Shandong University.
Plasma collection and PBMCs isolation
Five milliliters of venous peripheral blood was col-
lected from each subject, using EDTA as anticoagulant
agent. Plasma was collected after centrifugation and
stored at −80 °C for detection of cytokines. PBMCs
were isolated by gradient centrifugation via Ficoll-Paque
(Pharmacia Diagnostics, Uppsala, Sweden) according to
the manufacturer’s protocol and were stored at −20 °C
until use.
DNA and RNA extraction from PBMCs
Genomic DNA was extracted from PBMCs using
QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, CA,
USA) following the protocol provided by manufacturer
and stored at −20 °C. Total RNA was extracted by
phenol-chloroform-isopropanol method, purified, and
resuspended in 20 μL of RNase-free water.
Sodium bisulfate modification and MSP
The extracted DNA was treated with sodium bisulfite
using an EZ DNA methylation Kit (Zymo Research,
Orange, CA, USA) and then subjected to methylation-
specific polymerase chain reaction (MSP). Four pairs
of primers were used specifically to detect the PPAR-γ
gene promoter methylation status. The conditions for
PCR amplification were 40 cycles consisting of 30 s at
95 °C for denaturation, 40 s at 54.5 °C (CpG-1 island),
or 52 °C (CpG-2 island) for annealing and 30 s at 72 °C
for extension. The PCR products were separated via a
2.0 % agarose gel and visualized under UV illumination
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after staining with ethidium bromide. Primers were de-
signed based on the upstream sequence of PPAR-γ
gene [GenBank: NC_000003.12 (12287850-12471013)]
(Additional file 2: Figure S2), which were described in
our previous study [18] and listed in Additional file 3:
Table S1.
RT-PCR
Total RNA (1 μg per reaction) was converted into comple-
mentary DNA (cDNA) with PrimerScript™ RT Reagent Kit
(Perfect Real Time; Takara, Japan) according to the manu-
facturer’s instruction, with condition of 70 °C for 5 min
for denaturation and 42 °C for 60 min for reverse tran-
scription. The cDNA production was subjected to real-
time quantitative PCR (RT-PCR) to detect level of PPAR-γ
mRNA, and β-actin was used as the endogenous control.
The RT-PCR amplification mixtures (10 μL) included
0.5 mM each primer, 10 × SYBR Green (Toyobo, Osaka,
Japan) and 0.5 μL cDNA. The real-time PCR was per-
formed as follows: the initial step was 95 °C for 30 s,
followed by 40 cycles of 95 °C for 5 s, 60 °C for 30 s and
72 °C for 30 s. Data analysis was performed with the
LightCycler Software 4.0 (Roche Diagnostics, Germany),
and results were determined using the comparative (2−ΔCt,
ΔCt = Ct(PPAR-γ)-Ct(β-actin)) method.
ELISA for detection of plasma TNF-α and IL-6 level
Level of plasma cytokines was measured using Human
Tumor necrosis factor α ELISA Kit and Human Inter-
leukin 6 ELISA Kit (EIAab, Wuhan, China), according to
the standard protocols of the manufacturer. The mini-
mum detectable dose was typically 3.9 pg/mL for TNF-α
and 7.80 pg/mL for IL-6, respectively.
Clinical parameters
Fasting venous blood was collected from each subject.
Hepatitis B s antigen (HBsAg) and hepatitis B e antigen
(HBeAg) were detected by an electrochemiluminescence
assay (Roche Diagnostics Ltd, Mannheim, Germany). The
serum level of HBV DNA was assayed by a fluorescent
quantitative detection kit (Da An Gene, Guangzhou,
China). ALT, aspartate aminotransferase (AST), TBIL,
serum Cr, albumin (ALB), prothrombin activity (PTA),
and INR were measured by routine laboratory methods.
MELD scores were calculated according to the Malinchoc
formula: R = 9.57 × ln[creatinine(mg/dL)] + 3.78 × ln[bilir-
ubin(mg/dL)] + 11.2 × ln(INR) + 6.43 × (etiology: 0 if cho-
lestatic or alcoholic, 1 otherwise) [36].
Statistical analysis
All data were analyzed using SPSS 17.0 software (SPSS
Inc., Chicago, IL, USA). Comparison of methylation sta-
tus among different groups was analyzed by chi-square
test or Fisher’s exact test. Changes in mRNA
concentration were measured by Student t test or
Mann-Whitney U test. Spearman test was applied for cor-
relation analysis. Survival curves for methylated group and
unmethylated group of ACHBLF patients were com-
pared by Log-rank test. All statistical analyses were
two-sided and P value <0.05 was considered statisti-
cally significant.
Additional files
Additional file 1: Figure S1. Flowchart of subjects selection. The process
of inclusion and exclusion of subjects is shown. (DOC 30 kb)
Additional file 2: Figure S2. Schematic figure of peroxisome
proliferator-activated receptor gamma (PPAR-γ) gene promoter. CpG sites
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and annealing temperature are shown. (DOC 31 kb)
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